Compare CIM & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | AMPH |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | CIM | AMPH |
|---|---|---|
| Price | $13.61 | $21.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $15.25 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 658.7K | 614.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $1.62 | $6.90 |
| Revenue Next Year | $2.48 | $4.64 |
| P/E Ratio | ★ N/A | $150.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.67 | $16.65 |
| 52 Week High | $14.88 | $31.26 |
| Indicator | CIM | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 61.84 |
| Support Level | $13.05 | $16.84 |
| Resistance Level | $13.85 | $24.61 |
| Average True Range (ATR) | 0.26 | 0.85 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 83.70 | 85.85 |
Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.